Developing drugs to repair the kidney's filtering barrier in Alport syndrome
Alport syndrome is a rare inherited disease that damages the kidney's filtering barrier, allowing blood and protein to leak into urine. Kidney function can progressively decline to kidney failure. Current treatments can slow progression and preserve kidney function, but there is no cure.
Barriera Therapeutics develops small-molecule treatments for kidney disease, led by a programme for Alport syndrome. Its preclinical approach aims to repair the kidney's filtering barrier, using outsourced research to advance development toward the clinic.
What stands out about Barriera Therapeutics
Co-founder Tristan Heintz previously served as Chief Scientific Officer at Rejuveron Vascular Therapeutics.
Co-founder Joppe Nieuwenhuis also co-founded BIOIO, where he serves as COO developing therapeutics informed by the biology of ageing.
Co-founder Joppe Nieuwenhuis trained in functional genetics at the Netherlands Cancer Institute, using haploid genetic screens.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.